GlassScriptPhysician profile
George Hajjar
NPI 1619978715
$21,588.54
in general payments reported to CMS, 2019-2025
32 companies · $664 in 2025
The $664 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,087 · 2020: $5,504 · 2021: $30.93 · 2022: $9,517 · 2023: $149 · 2024: $3,637 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,825 · Grant: $350 · Food and Beverage: $192 · Education: $82.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,825.00 |
| Grant | $350.00 |
| Food and Beverage | $191.86 |
| Education | $82.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $9,439.42 | 2019-2022 | |
| Athenex Pharmaceutical Division, LLC | $3,850.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $3,209.02 | 2019-2024 | Imfinzi, Calquence, Lynparza |
| Incyte Corporation | $2,000.00 | 2020-2022 | |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Alexion Pharmaceuticals, INC. | $350.00 | 2024 | |
| Merck Sharp & Dohme LLC | $297.05 | 2019-2022 | |
| Pfizer INC. | $221.62 | 2019-2024 | |
| Sobi, INC | $200.00 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $193.02 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $122.12 | 2019 | |
| Medtronic USA, INC. | $112.53 | 2019 | |
| Seagen INC. | $104.39 | 2019-2023 | Adcetris |
| Intrinsiq Specialty Solutions, INC. | $100.00 | 2020 | |
| Cardinal Health 110 LLC | $100.00 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $77.93 | 2019 | |
| Clovis Oncology, INC. | $73.06 | 2019-2020 | |
| Genzyme Corporation | $69.87 | 2019 | |
| Eisai INC. | $63.27 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.75 | 2019 | |
| Puma Biotechnology, INC. | $41.91 | 2019 | |
| Genentech USA, INC. | $39.28 | 2019 | |
| Astellas Pharma US INC | $35.62 | 2019-2025 | Vyloy |
| Gilead Sciences, INC. | $34.47 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $26.50 | 2019 | |
| Emd Serono, INC. | $23.03 | 2019 | |
| Kyowa Kirin, INC. | $20.30 | 2019 | |
| Heron Therapeutics, INC. | $19.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.86 | 2019 | |
| Eusa Pharma (US) LLC | $16.46 | 2019 | |
| Lilly USA, LLC | $15.26 | 2019 | |
| Myriad Genetic Laboratories, INC. | $14.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Hajjar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.